PureTech Health plc (PRTC) Financial Analysis & Valuation | Quarter Chart
PureTech Health plc (PRTC)
PRTCPrice: $16.64
Fair Value: 🔒
🔒score
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The compan... more
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializ... more
Description
Shares
| Market Cap | $402.37M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Robert Lyne |
| IPO Date | 2020-11-16 | CAGR | -0.04% |
| Employees | 80 | Website | www.puretechhealth.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 23.87% | Total Yield | 23.87% |
PRTC chart loading...
Fundamentals
Technicals
| Enterprise Value | $150.99M | P/E Ratio | 9.79 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 86.94 | P/B Ratio | 1.29 |
| P/CF Ratio | -5.03 | P/FCF Ratio | -5.08 |
| EPS | $1.7 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -79.43% | Gross Margin | 3.39% |
| Operating Margin | -20.01% | Profit Margin | 8.62% |
| ROE | 0.13% | ROA | 0.09% |
| ROCE | -0.23% | Current Ratio | 8.49 |
| Quick Ratio | 8.49 | Cash Ratio | 6.42 |
| Debt/Equity | 0.06 | Interest Coverage | 305.63 |
| Altman Z Score | 1.9 | Piotroski Score | 2 |